- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02844504
Neurophysiological Evaluation of Training Effect on Cancer-Related Weakness
October 1, 2020 updated by: Kessler Foundation
Breast cancer patients often suffer from long-term physical symptoms of weakness.
In this study, investigators propose to compare how two different low intensity physical exercise training programs can improve handgrip strength for breast cancer patients with symptoms of weakness.
Using brain imaging, the study will also investigate changes in brain structure, and muscle activity associated with handgrip.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Participants will be randomized to either a no treatment group or one of two low intensity 6-week exercise training.
Outcomes will be measured at baseline, post-intervention and 4 weeks post intervention.
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
West Orange, New Jersey, United States, 07052
- Kessler Institute for Rehabilitation
-
West Orange, New Jersey, United States, 07052
- Kessler Foundation
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female aged 40-75 yrs
- Right handed, as determined by the Edinburgh Inventory (Oldfield, 1971)
- Proficient in English
- Must be available for the familiarization, and testing sessions
Exclusion Criteria:
- Symptoms for mild or severe depression as determined by a Patient Health Questionnaire (PHQ-8) score >14
- Significant cognitive impairments as defined by a score <28 in the Folstein Mini-Mental Screening Examination (MMSE, Folstein et al .1975).
- Participated in any type of motor imagery or strength training program in the last 5 years, or plan to start any motor imagery or physical strength training program for the 3 months duration of the study
- Neurological, psychiatric, musculoskeletal or other types of disorder that may affect participants sensorimotor function and cognitive abilities
- Current medication believed to affect cognitive/psychomotor function (i.e., opioid, analgesics, anxiolytics or antidepressants)
- History of alcohol, smoking, and drug abuse
- Any contraindication for MRI
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Low Intensity Exercise Training 1
Cancer survivors will receive low intensity handgrip exercise training.
|
Subjects will perform handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
|
|
Experimental: Low Intensity Exercise Training 2
Cancer survivors will receive low intensity handgrip exercise training different than other arm.
|
Subjects will perform a different handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
|
|
No Intervention: Control
This group will receive no training.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hand grip force
Time Frame: Pretest (before training), Posttest (immediately after end of training), Retention test (4 weeks after end of training)
|
Primary outcome will be used to compare pre to post change in maximum force contraction at the end of the 6-week intervention between groups.Similar comparison will be done between retention test (4 weeks after training) and posttest (immediately after training).
|
Pretest (before training), Posttest (immediately after end of training), Retention test (4 weeks after end of training)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pre to Post changes of functional brain to muscle coupling at maximum handgrip contraction
Time Frame: Pretest (before training), Posttest (immediately after end of training), Retention test (4 weeks after end of training)
|
Functional brain to muscle coupling will be measured by computing the EMG-EEG coherence before training, after training, and 4 weeks after end of intervention.
Values will be compared between groups.
|
Pretest (before training), Posttest (immediately after end of training), Retention test (4 weeks after end of training)
|
|
Pre to Post changes in EMG amplitude at maximum handgrip contraction
Time Frame: Pretest (before training), Posttest (immediately after end of training), Retention test (4 weeks after end of training)
|
EMG of the right arm muscles will be assessed during maximum handgrip contraction before training, after training, and 4 weeks after end of intervention.
Values will be compared between groups.
|
Pretest (before training), Posttest (immediately after end of training), Retention test (4 weeks after end of training)
|
|
Pre to Post changes in Brain activity during maximum handgrip contraction
Time Frame: Pretest (before training), Posttest (immediately after end of training)
|
functional magnetic resonance imaging will used to measure brain activity when subject performs maximum muscle handgrip contraction before training, after training.
Values will be compared between groups.
|
Pretest (before training), Posttest (immediately after end of training)
|
|
Functional brain to muscle (EEG-EMG) phase coupling at low intensity handgrip muscle contraction.
Time Frame: Pretest (before training), Posttest (immediately after end of training), Retention test (4 weeks after end of training)
|
Corticomuscular coherence between EEG signal from contralateral motor region and EMG signal from handgrip muscles will be computed while subjects perform handgrip contraction at 20% of their maximum force.Group x Time interaction will be measured.
|
Pretest (before training), Posttest (immediately after end of training), Retention test (4 weeks after end of training)
|
|
EEG Brain connectivity during low intensity handgrip muscle contraction
Time Frame: Pretest (before training), Posttest (immediately after end of training)
|
functional connectivity within the brain networks will be studied while subjects perform 20% of their maximum handgrip contraction.
Group x Time interaction will be measured.
|
Pretest (before training), Posttest (immediately after end of training)
|
|
Fatigue sustained handgrip contraction task duration
Time Frame: Pretest (before training), Posttest (immediately after end of training), Retention test (4 weeks after end of training)
|
Subjects will perform a sustained handgrip contraction task at 20% maximal force.The task duration (a measure of endurance) will be measured for each subject in the three groups, before and after training, and after 4 weeks of end of intervention.
Group x Time interaction will be measured.
|
Pretest (before training), Posttest (immediately after end of training), Retention test (4 weeks after end of training)
|
|
functional brain to muscle coupling during fatigue
Time Frame: Pretest (before training), Posttest (immediately after end of training), Retention test (4 weeks after end of training)
|
EMG-EEG coherence will be studied when subjects get fatigue after performing a sustained muscle contraction task at 20% maximal force.
Group x Time interaction will be measured.
|
Pretest (before training), Posttest (immediately after end of training), Retention test (4 weeks after end of training)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Guang Yue, PhD, Kessler Foundation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2016
Primary Completion (Actual)
September 1, 2020
Study Completion (Actual)
September 1, 2020
Study Registration Dates
First Submitted
June 23, 2016
First Submitted That Met QC Criteria
July 21, 2016
First Posted (Estimate)
July 26, 2016
Study Record Updates
Last Update Posted (Actual)
October 5, 2020
Last Update Submitted That Met QC Criteria
October 1, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R-849-14
- 5R01CA189665-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Low Intensity Exercise Training 1
-
Peking University Third HospitalRecruitingObesity | Metabolic SyndromeChina
-
Gazi UniversityNot yet recruitingInterstitial Lung Disease (ILD)Turkey (Türkiye)
-
Istanbul UniversityUnknown
-
Hacettepe UniversityAnkara UniversityRecruitingLung Cancer | Non Small Cell Lung CancerTurkey
-
Cliniques universitaires Saint-Luc- Université...Fonds National de la Recherche Scientifique; Concerted Research ActionNot yet recruitingMetabolic Dysfunction-associated Steatotic Liver DiseaseBelgium
-
Teachers College, Columbia UniversityActive, not recruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | Spinocerebellar Ataxia Type 7United States
-
Uppsala UniversityNanjing Sport Institute; Nanjing Maigaoqiao Community Health Service CenterCompleted
-
Riphah International UniversityCompletedOverweight and ObesityPakistan
-
Swinburne University of TechnologyNational Sports Institute of MalaysiaCompletedHealthy | Overweight | Physical InactivityMalaysia
-
Riphah International UniversityCompleted